SILVER SPRING
Tauklarify cleared as tau PET imaging agent for Alzheimer's disease
- Sponsor
- Lantheus Holdings, Inc. $LNTH
- Drug
- Tauklarify · florquinitau F 18
- Indication
- Alzheimer's disease imaging
FDA approves Tauklarify (florquinitau F 18 injection), an F18-labeled tau PET imaging agent for use in Alzheimer's disease.
What this means
Tauklarify is a radioactive dye that sticks to tau protein tangles in the brain, allowing doctors to see them on a PET scan. The FDA has cleared it for use in evaluating adult patients with cognitive impairment who are being assessed for Alzheimer's disease. This provides a new tool to help confirm the presence of Alzheimer's pathology, which may aid in diagnosis and patient management.